SpringWorks Therapeutics Performance
| SWTXDelisted Stock | USD 46.99 0.00 0.00% |
On a scale of 0 to 100, SpringWorks Therapeutics holds a performance score of 20. The entity has a beta of -0.31, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning SpringWorks Therapeutics are expected to decrease at a much lower rate. During the bear market, SpringWorks Therapeutics is likely to outperform the market. Please check SpringWorks Therapeutics' maximum drawdown, skewness, market facilitation index, as well as the relationship between the downside variance and rate of daily change , to make a quick decision on whether SpringWorks Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in SpringWorks Therapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, SpringWorks Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 176.7 M |
SpringWorks |
SpringWorks Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,706 in SpringWorks Therapeutics on April 19, 2025 and sell it today you would earn a total of 993.00 from holding SpringWorks Therapeutics or generate 26.79% return on investment over 90 days. SpringWorks Therapeutics is currently generating 0.4921% in daily expected returns and assumes 1.8669% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than SpringWorks, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SpringWorks Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SpringWorks Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SpringWorks Therapeutics, and traders can use it to determine the average amount a SpringWorks Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2636
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SWTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.87 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.49 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.26 actual daily | 20 80% of assets perform better |
Based on monthly moving average SpringWorks Therapeutics is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SpringWorks Therapeutics by adding it to a well-diversified portfolio.
SpringWorks Therapeutics Fundamentals Growth
SpringWorks Stock prices reflect investors' perceptions of the future prospects and financial health of SpringWorks Therapeutics, and SpringWorks Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SpringWorks Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.16) % | ||||
| Operating Margin | (1.64) % | ||||
| Current Valuation | 3.26 B | ||||
| Shares Outstanding | 75.35 M | ||||
| Price To Earning | 6.14 X | ||||
| Price To Book | 8.49 X | ||||
| Price To Sales | 16.12 X | ||||
| Revenue | 191.59 M | ||||
| EBITDA | (278.13 M) | ||||
| Cash And Equivalents | 334.54 M | ||||
| Cash Per Share | 6.81 X | ||||
| Total Debt | 7.91 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | (175.6 M) | ||||
| Earnings Per Share | (3.41) X | ||||
| Total Asset | 587.28 M | ||||
| Retained Earnings | (1.15 B) | ||||
| Current Asset | 29.13 M | ||||
| Current Liabilities | 10.16 M | ||||
About SpringWorks Therapeutics Performance
Evaluating SpringWorks Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SpringWorks Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SpringWorks Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.Things to note about SpringWorks Therapeutics performance evaluation
Checking the ongoing alerts about SpringWorks Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SpringWorks Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SpringWorks Therapeutics is not yet fully synchronised with the market data | |
| SpringWorks Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 191.59 M. Net Loss for the year was (258.13 M) with profit before overhead, payroll, taxes, and interest of 204.8 M. | |
| SpringWorks Therapeutics currently holds about 334.54 M in cash with (175.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81. | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Growth Stocks To Watch Today June 27th |
- Analyzing SpringWorks Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SpringWorks Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining SpringWorks Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SpringWorks Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SpringWorks Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SpringWorks Therapeutics' stock. These opinions can provide insight into SpringWorks Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in SpringWorks Stock
If you are still planning to invest in SpringWorks Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SpringWorks Therapeutics' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |